Forte Biosciences, Inc. (37T)

Profile

https://www.fortebiorx.com

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and autoimmune-related diseases. The company’s core activity today centers on advancing FB-102, a proprietary anti-CD122 monoclonal antibody designed to modulate immune pathways implicated in conditions such as graft-versus-host disease, vitiligo, alopecia areata, celiac disease, and type 1 diabetes. Operating within the biotechnology and pharmaceutical preparations sectors, Forte Biosciences targets areas of high unmet medical need, aiming to address complex, immune-driven disorders with targeted biologic interventions. Its development programs are currently in preclinical and early clinical stages, placing the company firmly in the clinical-stage category with no commercialized products yet. Forte Biosciences is headquartered in Dallas, Texas, United States, where it concentrates research, development, and corporate functions. By focusing on novel antibody-based treatments for systemic autoimmune conditions, Forte Biosciences plays a specialized role in the healthcare market as an innovator in immune-modulating therapeutics.